Facio names US ambassador

September 8, 2017

Facio Therapies announced today that Jennifer Burgess has agreed to become Facio’s ambassador to the FSHD community in the USA. Ms Burgess will raise awareness of Facio’s mission and progress among American FSHD-affected families, their friends and healthcare impact investors. Read more

 

 

Facio expands Board

June 30, 2017

Facio Therapies announced today that Cord Dohrmann, David Mackay, and Chip Wilson have joined its Board.  Facio’s Board was expanded in conjunction with the successful raise of €4.8M in equity that Facio announced on 20 June, 2017. Read more

 

 

Facio raises €4.8M from the FSHD community and Evotec

June 20, 2017

Facio Therapies announced today that it had raised €4.8M (approximately A$7.1M or US$5.4M) in equity financing from a global investor syndicate composed of FSHD-affected families from Australia, Europe, and North America; the French patient organization, Amis FSH; and Facio’s drug discovery partner, German-based Evotec. Read more

 

 

FSHD Unlimited publishes 2016 Annual Report

Facio provides updates on operational progress and financial results

May 5, 2017

Facio Therapies announced today that its parent company, FSHD Unlimited, published its audited Annual Report for the year 2016. Having raised €875,000 in equity, the Facio group of companies ended the report period with €1.1M in cash and cash equivalents. Expenses were mainly directed at Facio’s drug discovery program, resulting in 300+ validated hits early 2017 with the potential to tackle the cause of FSHD. These results enable Facio to start building a portfolio of DUX4-repressing compounds representing multiple shots on goal. Read more

 

 

Facio presents at the 6th annual Orphan Drugs and Rare Diseases Europe Conference

May 5, 2017

Facio Therapies will present its mission to improve the lives of people with FSHD, and showcase the latest results from its FSHD drug discovery program at the 6th annual Orphan Drugs and Rare Diseases Europe Conference in Berlin, Germany, on May 15th, 2017. Read more 

 

 

Facio presents at AMIS FSH patient meeting

May 5, 2017

Facio Therapies is invited to present at the AMIS FSH patient meeting in Paris, France on May 13th, 2017. Read more

 

 

Facio validates over 300 compounds with the potential to tackle the cause of FSHD

April 3, 2017

Facio Therapies announced today that it has validated more than 300 compounds (so-called “hits”) that repress the production of the muscle-toxic DUX4 protein in cultured muscle cells derived from FSHD patient biopsies. Undue production of DUX4 in skeletal muscle is the cause of FSHD. Read more

 

 

Facio screens 34,000 compounds

December 28, 2016

Facio Therapies announced today that it has screened approximately 34,000 compounds for their ability to repress the production of the muscle-toxic DUX4 protein in cultured muscle cells derived from FSHD patient biopsies. As planned, a variety of compounds with the desired effect (known as “hits”) have been identified. Read more

 

 

Facio presents its business approach at the Dutch Life Sciences Conference

November 17, 2016

Facio Therapies will present its business approach at the Dutch Life Sciences Conference in Leiden, the Netherlands, on November 24th, 2016. Read more

 

 

Growing FSHD community support for Facio

November 14, 2016

Facio Therapies announced today that the Dutch FSHD Foundation (FSHD Stichting) and the FSHD Canada Foundation have joined its shareholder base, which already included the FSHD Global Research Foundation and FSHD-affected families. New and existing investors together provided over €865,000 (about US$960,000) in new equity funding. Read more

 

Facio presents FSHD drug discovery progress at the World Orphan Drug Congress

November 9, 2016

Facio Therapies will present its progress in facioscapulohumeral dystrophy (FSHD) drug discovery at the World Orphan Drug Congress Europe in Brussels, Belgium, on November 17th, 2016. Read more

 

 

Facio develops breakthrough tool for FSHD drug discovery

August 31, 2016

Facio Therapies has established the first-ever validated platform that enables screening large numbers of compounds for their ability to repress the production of the DUX4 protein in cultured muscle cells derived from FSHD patient biopsies. With this tool, Facio expects to identify series of compounds with the desired effect before the end of 2016. Read more

 

 

FSHD Unlimited publishes its first Annual Report

Facio provides updates on operational progress and financial results

June 27, 2016

 

FSHD Unlimited, the parent company of both Facio Therapies and Facio Intellectual Property, has published its first audited Annual Report, which covers the period of September 2014 (inception) through December 2015.
Read more

 

  

Facio presents at AMIS FSH patient meeting 

March 16, 2016

Facio Therapies is invited to present at the AMIS FSH patient meeting in Lyon, France on March 19th, 2016. Read more

 

 

Facio presents at Friends of FSH Research Summit

February 26, 2016

Facio Therapies will present at the Friends of FSH Research Summit, which will be held on February 29th and March 1st, 2016 in Portland, Oregon USA. Read more

 

 

Facio obtains funding from the Dutch FSHD Foundation 

February 24, 2016

Facio Therapies has received support from the FSHD Stichting (“Dutch FSHD Foundation”) for a total of €100,000 (about 110,000 USD) for its drug discovery program towards a causal therapy for FSHD. Read more

 

 

Facio strengthens its Board

February 10, 2016

Facio Therapies announces that Otto Postma has been appointed to the Board of FSHD Unlimited as per February 11, 2016. Read more

 

 

Facio successfully completes first equity round with close to €2.5M in total proceeds

October 2, 2015

Facio Therapies has obtained close to €500,000 in equity funding from the FSHD Global Research Foundation as well as private investors from both within and outside the FSHD community. These funds are in addition to the €2 million equity financing raised in 2014. Read more

 

 

Facio enters into agreement with scientific leaders to advance its drug discovery program

June 23, 2015

Leading academic institutes active in the field of FSHD have agreed to transfer materials to Facio for its drug discovery program aimed at stopping the progression of FSHD. Read more

 

 

Facio partners with Evotec and initiates FSHD drug discovery program

April 29, 2015

Facio Therapies and Evotec have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD. This agreement marks the start of finding a drug to overcome FSHD. Read more

 

Facio congratulates Bill Moss AO

January 28, 2015

Facio’s founding father and investor Bill Moss AO has been appointed Officer of the Order of Australia. He has succeeded in putting FSHD on the map and is dedicated to finding a treatment and cure for FSHD. Read more

 

Facio reinforces team

January 16, 2015

Facio Therapies has retained Joris De Maeyer and Lars Bastiaanse to support its drug discovery and development program aimed at stopping the progression of FSHD. Joris is responsible for drug discovery and early development, while Lars is responsible for Facio’s overall drug development strategy. Read more

 

Facio raises €2 million

November 6, 2014

Facio Therapies has secured €2 million (about US$ 2.5 million) in initial financing from founding investors Kees van der Graaf and Bill Moss AM. Facio will use these funds towards its drug development program, which is aimed at stopping the progression of FSHD. Read more

 

Facio attends 2014 FSH Society Workshop

October 16, 2014 

Facio Therapies will attend the 2014 FSH Society International Research Consortium Workshop, which will be held on October 17-18, 2014, prior to the opening of the American Society for Human Genetics (ASHG) Meeting in San Diego, California USA. Read more